The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low?

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 727-734

  Förster, Werner ^a,b   Parratt, James Roy ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b NONE   (Germany)

Author keywords

Aspirin; Gastrointestinal mucosal injury; Myocardial infarction; Prostacyclin; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; PROSTACYCLIN; THROMBOXANE;

ARTICLE; ENDOTHELIUM CELL; HEART INFARCTION; HEART PROTECTION; HEART REINFARCTION; PRIORITY JOURNAL; THROMBOCYTE; UNSTABLE ANGINA PECTORIS;

EID: 0030894130     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053030     Document Type: Article

References (51)

1. Fuster V, Chesebro JH. Aspirin for primary prevention of coronary disease. Eur Heart J 1986;16(Suppl E):16-20.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
3. The Dutch TIA Trial Study Group. A comparison on two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
4. Underwood MJ, More RS. The aspirin papers. Aspirin benefits patients with vascular disease and those undergoing revascularisation. Br Med J 1994;308:71-72.
5. Parratt JR. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res 1993;27:693-702.
6. Vane J, Botting RM. A better understanding of antiinflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv Prostaglandin Thromboxane Leukot Res 1995;23:41-48.
7. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isoenzymes-1 and -2. In: FitzGerald GA, Jennings LK, Patrono C, eds. Platelet-Dependent Vascular Occlusion. Ann NY Acad Sci 1994; 714:136-142.
8. Henriksson P, Wennmalm A, Edhag O, Versterqvist O, Green K. In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986;55:543-548.
9. Mueller HS, Rao PS, Greenberg MA, et al. Systemic and transcardiac platelet activity in acute myocardial infarction in man: Resistance to prostacyclin. Circulation 1985;72: 1336-1345.
10. Bassenge E. Control of coronary blood flow by autacoids. Basic Res Cardiol 1995;90:125-141.
11. 2 balance: Pathophysiological and therapeutic implications. Br Med Bull 1983;39:271-276.
12. 2, malondialdehyde and platelet sensitivity to 3 weeks low-dose aspirin (ASA) on healthy volunteers. Thromb Res 1989;53:261-269.
13. Sinzinger H, Silberbauer K, Kaliman J, Fitscha P. 20 mg aspirin daily - evidence for a clinical future of this extremely low-dose in arterial disease? Vasa 1988;17:10-15.
14. Knapp HR, Healy C, Lawson J, FitzGerald GA. Effects of low-dose aspirin on endogenous eicosanoid fomation in normal and atherosclerotic men. Thromb Res 1988;50:377-386.
15. De Caterina R, Gianessi D, Bernini W, et al. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J 1985;6:409-417.
16. Hoffmann W, Förster W. Two years Cottbus reinfarction study with 30 mg aspirin per day. Prostaglandins Leukot Essent Fatty Acids 1991;44:159-169.
17. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-1184.
18. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D. Eicosanoid biosynthesis in patients with stable angina: Beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994;24:33-38.
19. Keimowitz R, McAdams B, Maher M, Fitzgerald D. A dermal aspirin preparation (patch) with undetectable systemic bioavailability results in marked suppression of platelet cyclooxygenase (abstr). Circulation 1995;92(Suppl):2334.
20. 2 but not of systematic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325:1137-1141.
21. FitzGerald GA, Oates JA. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35:633-640.
22. Kallmann R, Nieuwenhuis HK, de Groot PG, van Gijn J. Sixma JJ. Effects of low-dose aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1α excretion in healthy subjects. Thromb Res 1987;45:355-361.
23. Böger RH, Bode-Böger SM, Tsikas D, Frölich JC. Increased prostacyclin production during submaximal exercise in trained and untrained subjects: Effect of low-dose aspirin administration. Eur J Clin Pharmacol 1994;47:A94.
24. Hanley SP, Bevan J, Cockbill SR, Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1981;1:969-971.
25. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invent 1983; 71:676-688.
26. Whittle BJR, Moncada S, Vane JR. Some actions of prostacyclin (PGI2) on the cardiovascular system and the gastric microcirculation. Acta Biol Med Germ 1978;37:725-728.
27. Coker SJ, Parratt, JR. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J Mol Cell Cardiol 1984;16:43-52.
28. Parratt JR. Eicosanoids and arrhythmogenesis. In: Vaughan Williams EM, ed. Antiarrhythmic Drugs. Berlin: Springer, 1989:569-589.
29. Gryglewski RJ. Interactions between nitric oxide and prostacyclin. Semin Thromb Hemost 1993;19:158-166.
30. Sinzinger H, Grady J, Fitscha P, Kaliman J. Extremely-low-dose aspirin (one milligram per day) renders human platelets more sensitive to antiaggregation prostaglandins. N Engl J Med 1984;311:1052.
31. Förster W. Prostaglandins and prostaglandin precursors as endogenous antiarrhythmic principles of the heart. Acta Biol Med Germ 1976;35:1101-1112.
32. Coker SJ, Parratt JR. Aspirin in the early stages of myocardial infarction. R. Soc Med Int Congr Symp Series No 1984; 71:71-75.
33. Parratt JR, Coker SJ, Wainwright CL. Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. J Mol Cell Cardiol 1987;19 (Suppl 5):55-66.
34. Wainwright C, Parratt JR. Myocardial Preconditioning. Berlin: Springer, 1996.
35. Parratt JR, Szekeres L. Delayed protection of the heart against ischaemia. Trends Pharmacol Sci 1995;16:351-355.
36. Beitz J, Förster W. Influence of human low density and high density lipoprotein cholesterol on the in vitro prostaglandin 12 synthetase activity. Biochim Biophys Acta 1980; 620:352-355.
37. Förster W, Beitz J, Hoffmann P. Stimulation and inhibition of PGI2 synthetase activity by phospholipids (PL), cholesterol esters (CE), unesterified fatty acids (UFA) and lipoproteins (LDL and HDL). Artery 1980;8:494-500.
38. Giessler Ch, Beitz J, Mentz P, Förster W. The influence of lipoproteins (LDL and HDL) on PGI2-formation by isolated aortic preparations of rabbits. Prostaglandins Leukot Med 1986;22:221-234.
39. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I): A novel function of apo A-I. J Clin Invest 1988;82:803-807.
40. Kawai C. Pathogenesis of acute myocardial infarction. Novel regulatory systems of bioactive substances in the vessel wall. Circulation 1994;9:1033-1043.
41. Sato Y, Asaka M, Takeda H, Ohtaki T, Miyazaki T. The mechanism of aspirin-induced gastric mucosal injury. J Clin Gastroenterol 1993;17:S1-S4.
42. Whittle BJR. Arachidonic acid metabolites and the gastrointestinal toxicity of anti-inflammatory agents. Prostaglandins 1981;21(Suppl):113-118.
43. Müller P, Dammann HG, Marinis E, Simon B. Gastroduodenale Verträglichkeit von 30 mg versus 300 mg Acetylsalicylsäure täglich. Med Klin 1990;85:429-431.
44. Müller P, Dammann HG, Marinis E, Simon B. Endoskopische Untersuchungen zur gastroduodenalen Verträglichkeit 100 mg versus 500 Acetylsalicylsaure täglich: eine randomisierte Doppelblindstudie an gesunden Probanden. Z Gastroenterol 1989;27:418-420.
45. Nair M, Sethi KK. Low dose aspirin therapy in prophylaxis of cardiovascular disease - How low is low? Indian Heart J 1992;44:371-372.
46. Hoffmann W, Förster W. Zweijahresstudie an den Herzinfarkt-Patienten des Bezirkes Cottbus mit 30, 60 und 1000 mg Acetylsalicylsaure (ASS) je Tag-Einfluß auf Reinfarkt-Morbidität und Letalität. Z Klin Med 1987;42:2097-2101.
47. Förster W. Reinfarkt-Prophylaxe mit niedrigdosierter ASS. Münch Med Wschr 1993;135:80-84.
48. Braun M, Kramann J, Strobach H, Schrör K. Incomplete inhibition of platelet secretion by low-dose aspirin. Platelets 1994;5:325-331.
49. Buerke M, Pittroff W, Meyer J, Darius H. Aspirin therapy - optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995;130:465-472.
50. Darius H, Sellig S, Belz GG, Darius BN. Aspirin 500 mg/ d is superior to 100 and 40 mg/d for prevention of restenosis following PTCA. Circulation 1994;90(Suppl):abstr 3507.
51. Förster W. Reinfarktprophylaxe mit 100 mg oder 30 mg ASS täglich? Z Kardiol 1995;84:335-343.